MX368496B - Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. - Google Patents

Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.

Info

Publication number
MX368496B
MX368496B MX2016013265A MX2016013265A MX368496B MX 368496 B MX368496 B MX 368496B MX 2016013265 A MX2016013265 A MX 2016013265A MX 2016013265 A MX2016013265 A MX 2016013265A MX 368496 B MX368496 B MX 368496B
Authority
MX
Mexico
Prior art keywords
pyrazolo
analogues
parp inhibitors
benzimidazole compound
compound
Prior art date
Application number
MX2016013265A
Other languages
English (en)
Other versions
MX2016013265A (es
Inventor
Chen Shuhui
Xu Yong
Wang Xuehai
Li Lie
Tu Ronghua
Yue Yang
Chen Hailiang
Sun Wenjie
Huang Lu
Li Gang
Wang Cailin
Zhang Zhibo
Ding Zhaozhong
Original Assignee
Humanwell Healthcare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN201410144173.0A external-priority patent/CN104974161B/zh
Application filed by Humanwell Healthcare Group Co Ltd filed Critical Humanwell Healthcare Group Co Ltd
Publication of MX2016013265A publication Critical patent/MX2016013265A/es
Publication of MX368496B publication Critical patent/MX368496B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se da a conocer una serie de análogos del compuesto 4H-pirazolo[1,5-?]bencimidazol como inhibidores de PARP; en particular, se describe en la invención un compuesto tal como se muestra por la fórmula (I) o una sal farmacéuticamente aceptable del mismo como un inhibidor de PARP.
MX2016013265A 2014-04-10 2015-03-30 Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp. MX368496B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410144173.0A CN104974161B (zh) 2014-04-10 2014-04-10 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CN201510113090 2015-03-13
PCT/CN2015/075363 WO2015154630A1 (zh) 2014-04-10 2015-03-30 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Publications (2)

Publication Number Publication Date
MX2016013265A MX2016013265A (es) 2017-05-03
MX368496B true MX368496B (es) 2019-10-04

Family

ID=54287319

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013265A MX368496B (es) 2014-04-10 2015-03-30 Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.

Country Status (22)

Country Link
US (1) US9856262B2 (es)
EP (1) EP3130592B1 (es)
JP (1) JP6359175B2 (es)
KR (1) KR101921486B1 (es)
CN (1) CN106459057B (es)
AU (1) AU2015245786B2 (es)
BR (1) BR112016023397B1 (es)
CA (1) CA2944801C (es)
DK (1) DK3130592T3 (es)
ES (1) ES2754590T3 (es)
HU (1) HUE047410T2 (es)
IL (1) IL248258B (es)
MX (1) MX368496B (es)
NZ (1) NZ725165A (es)
PL (1) PL3130592T3 (es)
PT (1) PT3130592T (es)
RU (1) RU2672722C2 (es)
SA (1) SA516380051B1 (es)
SG (1) SG11201608438YA (es)
TW (1) TWI671301B (es)
WO (1) WO2015154630A1 (es)
ZA (1) ZA201607736B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974161B (zh) * 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CA3003122C (en) * 2015-09-30 2023-10-03 Medshine Discovery Inc. Salt type and crystal type of 4h-pyrazolo[1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
KR102596307B1 (ko) 2017-04-27 2023-10-30 바이엘 애니멀 헬스 게엠베하 새로운 비시클릭 피라졸 유도체
CN116969954B (zh) * 2023-09-21 2023-11-28 广东省农业科学院农业质量标准与监测技术研究所 一类含内酰胺的三环稠合杂环化合物及其应用
CN117534677B (zh) * 2024-01-09 2024-03-12 广东省农业科学院农业质量标准与监测技术研究所 一类含亚胺的三环稠合杂环化合物及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916051A (en) * 1987-04-07 1990-04-10 Konica Corporation Silver halide color photographic light-sensitive material
RU2394035C2 (ru) * 2003-12-22 2010-07-10 Эс Би ФАРМКО ПУЭРТО РИКО ИНК. Антагонисты crf-рецепторов и способы, относящиеся к ним
EP1973909A2 (en) * 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
WO2007144669A1 (en) * 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
CN101506214A (zh) * 2006-06-20 2009-08-12 艾博特公司 作为parp抑制剂的吡唑并喹唑啉酮
GB0701273D0 (en) * 2007-01-24 2007-02-28 Angeletti P Ist Richerche Bio New compounds
EP2656843B1 (en) 2012-04-26 2015-03-18 Helmut Schickaneder Esters of bendamustine and related compounds, and medical use thereof
EA027628B1 (ru) 2012-05-04 2017-08-31 Мерк Патент Гмбх Производные пирролотриазинона
EP2666775A1 (en) 2012-05-21 2013-11-27 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
WO2013182580A1 (en) 2012-06-07 2013-12-12 F. Hoffmann-La Roche Ag Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase
IN2015MN00002A (es) * 2012-07-09 2015-10-16 Lupin Ltd
CN103570725B (zh) 2012-08-01 2017-03-22 中国科学院上海药物研究所 哌嗪并三唑类化合物及其制备方法和用途
PT2882714T (pt) * 2012-08-08 2020-02-19 Merck Patent Gmbh Derivados de (aza)isoquinolinona
CN104974161B (zh) 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物

Also Published As

Publication number Publication date
PT3130592T (pt) 2019-11-21
CA2944801A1 (en) 2015-10-15
RU2672722C2 (ru) 2018-11-19
EP3130592A1 (en) 2017-02-15
AU2015245786A1 (en) 2016-11-03
CN106459057B (zh) 2019-06-07
SG11201608438YA (en) 2016-11-29
AU2015245786B2 (en) 2018-03-15
IL248258B (en) 2018-11-29
TW201620913A (zh) 2016-06-16
ES2754590T3 (es) 2020-04-20
US20170029430A1 (en) 2017-02-02
EP3130592A4 (en) 2017-09-06
PL3130592T3 (pl) 2020-05-18
HUE047410T2 (hu) 2020-04-28
RU2016144202A3 (es) 2018-05-15
MX2016013265A (es) 2017-05-03
KR101921486B1 (ko) 2018-11-26
NZ725165A (en) 2018-04-27
CN106459057A (zh) 2017-02-22
RU2016144202A (ru) 2018-05-15
ZA201607736B (en) 2017-09-27
KR20170005807A (ko) 2017-01-16
BR112016023397A2 (es) 2017-08-15
EP3130592B1 (en) 2019-08-14
JP2017510653A (ja) 2017-04-13
WO2015154630A1 (zh) 2015-10-15
TWI671301B (zh) 2019-09-11
US9856262B2 (en) 2018-01-02
JP6359175B2 (ja) 2018-07-18
SA516380051B1 (ar) 2020-05-17
DK3130592T3 (da) 2019-11-04
BR112016023397B1 (pt) 2022-08-16
CA2944801C (en) 2019-02-12

Similar Documents

Publication Publication Date Title
SA518400547B1 (ar) مشتقات بيرازولو بيريميدين كمثبط كيناز
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12017501523A1 (en) Selective bace1 inhibitors
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
MA39749A (fr) Dérivés de pipéridine-dione
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
MX2018001992A (es) Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa.
JO3318B1 (ar) مثبطات bace
MX2020003020A (es) Compuestos de aminocarbonilcarbamato.
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MY193239A (en) Novel b-lactamase inhibitors
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
TW201613898A (en) Benzofuran analogue as NS4B inhibitor
MX2018002193A (es) Metodo de uso de quinoxalinilo-piperazinamida.
TW201613928A (en) Vinyl compounds as inhibitors for FGFR and VEGFR

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: HUMANWELL HEALTHCARE (GROUP) CO., LTD.

FG Grant or registration